Pay in 4 interest-free payments of $7.32 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
Semaglutide has been shown to be superior in promoting bodyweight reduction compared to other GLP-1 agonists, though, with the participants in a 2018 study using semaglutide exhibiting weight loss of more than 5%
Semaglutide (Wegovy) Semaglutide is a weekly injectable GLP-1 receptor agonist
The once-daily pill offers new oral cardiovascular risk-reduction option for plan members with diabetes Heart disease is still the second leading cause of death in Canada, and most Canadians have at least one risk factor now a oncedaily GLP1 pill adds a new option for adults with type 2 diabetes and cardiovascular risk
Lightweight jelly-serum formulated to visibly brighten skin and reduce the appearance of dark spots, age spots, sun spots, acne scars, post-acne marks, and skin discoloration associated with hyperpigmentation and melasma
Balances concentration with syringe precision | | 50mg | 5mL | 10mg/mL | 0.5mL (50 units) | 1.0mL (100 units) | Lower concentration improves measurement accuracy but uses solution faster | | 100mg | 2mL | 50mg/mL | 0.1mL (10 units) | 0.2mL (20 units) | Higher vial amount extends total doses but requires same precision as 50mg/1mL | | 100mg | 4mL | 25mg/mL | 0.2mL (20 units) | 0.4mL (40 units) | Optimal for multi-week protocols
